JanOne taps distinguished chemist Dr. Doug Flanagan as chief formulation advisor

Share this story

Dr. Flanagan, an accomplished chemist and formulation specialist, leads manufacturing and clinical development of JanOne’s PAD candidate TV1001SR

LAS VEGASJune 25, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, continues to build a world-class team of biopharma experts with the addition of  Douglas Flanagan, PhD as the company’s chief formulation advisor. Dr. Flanagan will work directly with CoreRX, JanOne’s manufacturing partner to ensure the integrity of TV1001SR, the company’s clinical candidate for treating Peripheral Artery Disease (PAD) expected soon to enter phase 2 trials.  He will also play an integral role for the potential identification and advancement of other clinical candidates to treat pain as the company hopes to broaden its pipeline in the near future.

Leave a Comment

Your email address will not be published. Required fields are marked *